Gyre Therapeutics, Inc. (GYRE)

Gyre Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	140.62	113.45	102.29	7.34	20.95	0
Revenue Growth (YoY)	11.23%	10.91%	1293.98%	-64.97%	-	-
Cost of Revenue	5.62	4.64	4.79	7.38	9.16	0
Gross Profit	135.01	108.81	97.5	-0.04	11.79	0
Selling, General & Admin	87.79	75.82	71.61	18.96	16.18	13.42
Research & Development	15.37	13.78	16.69	68.89	52.98	43.86
Other Operating Expenses	91.18	86.44	0	0	0	0
Operating Expenses	194.34	176.04	88.29	87.85	69.16	57.28
Operating Income	-59.34	-67.23	9.2	-87.89	-57.37	-57.28
Other Expense / Income	15.28	17.19	1.8	0.04	-1.13	-2.1
Pretax Income	-74.61	-84.42	7.4	-87.93	-56.24	-55.18
Income Tax	11.05	8.52	5.1	0	0	0
Net Income	-85.66	-92.93	2.3	-87.93	-56.24	-55.18
Shares Outstanding (Basic)	83	66	64	2	1	1
Shares Outstanding (Diluted)	103	66	76	2	1	1
Shares Change	30.00%	-13.02%	3605.16%	59.76%	59.77%	7.05%
EPS (Basic)	-1.47	-1.41	0.04	-43.05	-43.95	-69.00
EPS (Diluted)	-1.53	-1.41	0.03	-43.05	-43.95	-69.00
Free Cash Flow	26.96	18.04	5.69	-84.59	-55.32	-43.68
Free Cash Flow Per Share	0.32	0.27	0.09	-41.41	-43.26	-54.58
Dividend Per Share	-	3.600	21.450	-	-	-
Dividend Growth	-	-83.22%	-	-	-	-
Gross Margin	96.01%	95.91%	95.31%	-0.57%	56.26%	-
Operating Margin	-42.20%	-59.26%	9.00%	-1197.79%	-273.87%	-
Profit Margin	-60.92%	-81.92%	2.25%	-1198.32%	-268.48%	-
Free Cash Flow Margin	19.17%	15.90%	5.56%	-1152.82%	-264.06%	-
Effective Tax Rate	-	-	68.89%	-	-	-
EBITDA	-72.66	-82.99	8.89	-87.64	-56.1	-55.03
EBITDA Margin	-51.67%	-73.15%	8.69%	-1194.37%	-267.82%	-
Depreciation & Amortization	1.95	1.43	1.49	0.29	0.14	0.15
EBIT	-74.61	-84.42	7.4	-87.93	-56.24	-55.18
EBIT Margin	-53.06%	-74.41%	7.23%	-1198.32%	-268.48%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).